Biotransformations Leading to Toxic Metabolites. Chemical Aspect

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 674-696

  Macherey, Anne Christine ^a   Dansette, Patrick M ^b  

^a UPS 831   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882489824     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00033-0     Document Type: Chapter

References (102)

1. Williams R. Detoxication Mechanisms 1959, John Wiley & Sons, New York, p. 796. 2nd Edition.
2. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. evidence for its hemoprotein nature. J. Biol. Chem. 1964, 239:2370-2378.
3. Snyder R. Microsomal enzyme induction. Toxicol. Sci. 2000, 55:233-234.
4. Sipes G., Gandolfi A.J. Biotransformation of toxicants. Casarett and Doull' Toxicology: The Basic Science of Poisons 1991, 88-126. Pergamon Press, New York. 4th Edition. M.O. Amdur, J. Doull, C.D. Klaassen (Eds.).
5. Alvares A.P., Pratt W.B. Pathways of drug metabolism. Principles of Drug Action: The Basis of Pharmacology 1990, 227-300. Churchill Livingstone, New York. 3rd Edition. W.B. Pratt, P. Taylor (Eds.).
6. Josephy P.D., Guengerich F.P., Miners J.O. quot;Phase I and phase II" drug metabolism: terminology that we should phase out?. Drug Metab. Rev. 2005, 37:575.
7. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14:611-650.
8. Guengerich F.P. Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Arch. Biochem. Biophys. 2003, 409:59-71.
9. Isin E.M., Guengerich F.P. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim. Biophys. Acta 2007, 1770:314-329.
10. Mason R.P., Chignell C.F. Free radicals in pharmacology and toxicology - selected topics. Pharmacol. Rev. 1981, 33:189-211.
11. Aust S.D., Chignell C.F., Bray T.M., Kalyanaraman B., Mason R.P. Free radicals in toxicology. Toxicol. Appl. Pharmacol. 1993, 120:168-178.
12. Singal P.K., Petkau A., Gerrard J.M., Hrushovetz S., Foerster J. Free radicals in health and disease. Mol. Cell. Biochem. 1988, 84:121-122.
13. Anders M.W., Pohl L.R. Halogenated alkanes. Bioactivation of Foreign Compounds 1985, 284-315. Academic Press, Orlando, FL. M.W. Anders (Ed.).
14. Pohl L.R., Nelson S.D., Krishna G. Investigation of the mechanism of the metabolic activation of chloramphenicol by rat liver microsomes. Identification of a new metabolite. Biochem. Pharmacol. 1978, 27:491-496.
15. Halpert J.R., Miller N.E., Gorsky L.D. On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J. Biol. Chem. 1985, 260:8397-8403.
16. Fontana E., Dansette P.M., Poli S.M. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr. Drug Metab. 2005, 6:413-454.
17. Cresteil T., Beaune P., Leroux J.P., Lange M., Mansuy D. Biotransformation of chloroform by rat and human liver microsomes; in vitro effect on some enzyme activities and mechanism of irreversible binding to macromolecules. Chem. Biol. Interact. 1979, 24:153-165.
18. Benasutti M., Ejadi S., Whitlow M.D., Loechler E.L. Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences. Biochemistry 1988, 27:472-481.
19. Koen Y.M., Gogichaeva N.V., Alterman M.A., Hanzlik R.P. A proteomic analysis of bromobenzene reactive metabolite targets in rat liver cytosol in vivo. Chem. Res. Toxicol. 2007, 20:511-519.
20. Rietjens I.M., den Besten C., Hanzlik R.P., van Bladeren P.J. Cytochrome P450-catalyzed oxidation of halobenzene derivatives. Chem. Res. Toxicol. 1997, 10:629-635.
21. Verna L., Whysner J., Williams G.M. 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol. Ther. 1996, 71:83-105.
22. Dansette P.M., Thang D.C., el Amri H., Mansuy D. Evidence for thiophene-S-oxide as a primary reactive metabolite of thiophene in vivo: formation of a dihydrothiophene sulfoxide mercapturic acid. Biochem. Biophys. Res. Commun. 1992, 186:1624-1630.
23. Treiber A., Dansette P.M., ElAmri H., Girault J.P., Ginderow D., Mornon J.P., Mansuy D. Chemical and biological oxidation of thio-phene: preparation and complete characterization of thiophene S-oxide dimers and evidence for thiophene S-oxide as an intermediate in thiophene metabolism in vivo and in vitro. J. Am. Chem. Soc. 1997, 119:1565-1571.
24. Treiber A., Dansette P.M., Mansuy D. Mechanism of the aromatic hydroxylation of thiophene by acid-catalyzed peracid oxidation. J. Org. Chem. 2002, 67:7261-7266.
25. Dansette P.M., Bertho G., Mansuy D. First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives. Biochem. Biophys. Res. Commun. 2005, 338:450-455.
26. Dalvie D.K., Kalgutkar A.S., Khojasteh-Bakht S.C., Obach R.S., O'Donnell J.P. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol. 2002, 15:269-299.
27. Gaudiano G., Koch T.H. Redox chemistry of anthracycline antitumor drugs and use of captodative radicals as tools for its elucidation and control. Chem. Res. Toxicol. 1991, 4:2-16.
28. Garner A.P., Paine M.J., Rodriguez-Crespo I., Chinje E.C., Ortiz De Montellano P., Stratford I.J., Tew D.G., Wolf C.R. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 1999, 59:1929-1934.
29. Butler T.C. Reduction of carbon tetrachloride in vivo and reduction of carbon tetrachloride and chloroform in vitro by tissues and tissue constituents. J. Pharmacol. Exp. Ther. 1961, 134:311-319.
30. Mico B.A., Branchflower R.V., Pohl L.R. Formation of electrophilic chlorine from carbon tetrachloride - involvement of cytochrome P-450. Biochem. Pharmacol. 1983, 32:2357-2359.
31. Gross P. Biologic activity of hydroxylamine: a review. Crit. Rev. Toxicol. 1985, 14:87-99.
32. Mason R.P. Redox cycling of radical anion metabolites of toxic chemicals and drugs and the Marcus theory of electron transfer. Environ. Health Perspect. 1990, 87:237-243.
33. Grant D.M., Hughes N.C., Janezic S.A., Goodfellow G.H., Chen H.J., Gaedigk A., Yu V.L., Grewal R. Human acetyltransferase polymorphisms. Mutat. Res. 1997, 376:61-70.
34. Timbrell J.A., Mitchell J.R., Snodgrass W.R., Nelson S.D. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J. Pharmacol. Exp. Ther. 1980, 213:364-369.
35. Sinha B.K. Activation of hydrazine derivatives to free radicals in the perfused rat liver: a spin-trapping study. Biochim. Biophys. Acta 1987, 924:261-269.
36. Weber G.L., Steenwyk R.C., Nelson S.D., Pearson P.G. Identification of N-acetylcysteine conjugates of 1,2-dibromo-3-chloropropane: evidence for cytochrome P450 and glutathione mediated bioactivation pathways. Chem. Res. Toxicol. 1995, 8:560-573.
37. 14C]pyridine. Xenobiotica 1980, 10:151-157.
38. Videla L.A., Barros S.B., Junqueira V.B. Lindane-induced liver oxidative stress. Free Radic. Biol. Med. 1990, 9:169-179.
39. Miller E.C., Miller J.A. Mechanisms of chemical carcinogenesis. Cancer 1981, 47:1055-1064.
40. DeCaprio A.P., Strominger N.L., Weber P. Neurotoxicity and protein binding of 2,5-hexanedione in the hen. Toxicol. Appl. Pharmacol. 1983, 68:297-307.
41. Genter St Clair M.B., Amarnath V., Moody M.A., Anthony D.C., Anderson C.W., Graham D.G. Pyrrole oxidation and protein cross-linking as necessary steps in the development of gamma-diketone neuropathy. Chem. Res. Toxicol. 1988, 1:179-185.
42. Chen L.J., Hecht S.S., Peterson L.A. Characterization of amino acid and glutathione adducts of cis-2-butene-1,4-dial, a reactive metabolite of furan. Chem. Res. Toxicol. 1997, 10:866-874.
43. Baer B.R., Rettie A.E., Henne K.R. Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate. Chem. Res. Toxicol. 2005, 18:855-864.
44. Thomas S.H. Paracetamol (acetaminophen) poisoning. Pharmacol. Ther. 1993, 60:91-120.
45. Dahlin D.C., Miwa G.T., Lu A.Y., Nelson S.D. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc. Natl. Acad. Sci. USA 1984, 81:1327-1331.
46. Chen W., Koenigs L.L., Thompson S.J., Peter R.M., Rettie A.E., Trager W.F., Nelson S.D. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem. Res. Toxicol. 1998, 11:295-301.
47. Mitchell J.R., Jollow D.J., Gillette J.R., Brodie B.B. Drug metabolism as a cause of drug toxicity. Drug Metab. Dispos. 1973, 1:418-423.
48. Ramakrishna Rao D.N., Fischer V., Mason R.P. Glutathione and ascorbate reduction of the acetaminophen radical formed by peroxidase. Detection of the glutathione disulfide radical anion and the ascorbyl radical. J. Biol. Chem. 1990, 265:844-847.
49. Fischer V., West P.R., Harman L.S., Mason R.P. Free-radical metabolites of acetaminophen and a dimethylated derivative. Environ. Health Perspect. 1985, 64:127-137.
50. Dietze E.C., Schafer A., Omichinski J.G., Nelson S.D. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by a reactive metabolite of acetaminophen and mass spectral characterization of an arylated active site peptide. Chem. Res. Toxicol. 1997, 10:1097-1103.
51. 14C]acetaminophen to mouse hepatic microsomal proteins: the specific binding to calreticulin and the two forms of the thiol:protein disulfide oxidoreductases. Chem. Res. Toxicol. 1996, 9:1176-1182.
52. Welch K.D., Reilly T.P., Bourdi M., Hays T., Pise-Masison C.A., Radonovich M.F., Brady J.N., Dix D.J., Pohl L.R. Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem. Res. Toxicol. 2006, 19:223-233.
53. Rosen G.M., Singletary W.V., Rauckman E.J., Killenberg P.G. Acetaminophen hepatotoxicity. An alternative mechanism. Biochem. Pharmacol. 1983, 32:2053-2059.
54. Holownia A., Mapoles J., Menez J.F., Braszko J.J. Acetaminophen metabolism and cytotoxicity in PC12 cells transfected with cytochrome P4502E1. J. Mol. Med. 1997, 75:522-527.
55. Dai Y., Cederbaum A.I. Cytotoxicity of acetaminophen in human cytochrome P4502E1-transfected HepG2 cells. J. Pharmacol. Exp. Ther. 1955, 273:1497-1505.
56. Nelson S.D., Pearson P.G. Covalent and noncovalent interactions in acute lethal cell injury caused by chemicals. Annu. Rev. Pharmacol. Toxicol. 1990, 30:169-195.
57. Josephy P.D. The molecular toxicology of acetaminophen. Drug Metab. Rev. 2005, 37:581.
58. Homberg J.C., Andre C., Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin. Exp. Immunol. 1984, 55:561-570.
59. Dansette P.M., Bonierbale E., Minoletti C., Beaune P.H., Pessayre D., Mansuy D. Drug-induced immunotoxicity. Eur. J. Drug Metab. Pharmacokinet. 1998, 23:443-451.
60. Beaune P., Dansette P.M., Mansuy D., Kiffel L., Finck M., Amar C., Leroux J.P., Homberg J.C. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. USA 1987, 84:551-555.
61. Lopez-Garcia M.P., Dansette P.M., Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994, 33:166-175.
62. Lecoeur S., Bonierbale E., Challine D., Gautier J.C., Valadon P., Dansette P.M., Catinot R., Ballet F., Mansuy D., Beaune P.H. Specificity of in vitro covalent binding of tienilic acid metabolites to human liver microsomes in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic drugs. Chem. Res. Toxicol. 1994, 7:434-442.
63. Mansuy D. Molecular structure and hepatotoxicity: compared data about two closely related thiophene compounds. J. Hepatol. 1997, 26(Suppl 2):22-25.
64. Lopez Garcia M.P., Dansette P.M., Valadon P., Amar C., Beaune P.H., Guengerich F.P., Mansuy D. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur. J. Biochem. 1993, 213:223-232.
65. Masubuchi Y., Horie T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit. Rev. Toxicol. 2007, 37:389-412.
66. Robin M.A., Maratrat M., Le Roy M., Le Breton F.P., Bonierbale E., Dansette P., Ballet F., Mansuy D., Pessayre D. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J. Clin. Invest. 1996, 98:1471-1480.
67. Neuberger J., Williams R. Immune mechanisms in tienilic acid associated hepatotoxicity. Gut 1989, 30:515-519.
68. Valadon P., Dansette P.M., Girault J.P., Amar C., Mansuy D. Thiophene sulfoxides as reactive metabolites: formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo. Chem. Res. Toxicol. 1996, 9:1403-1413.
69. Koenigs L.L., Peter R.M., Hunter A.P., Haining R.L., Rettie A.E., Friedberg T., Pritchard M.P., Shou M., Rushmore T.H., Trager W.F. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 1999, 38:2312-2319.
70. Harris J.W., Pohl L.R., Martin J.L., Anders M.W. Tissue acylation by the chlorofluorocarbon substitute 2,2-dichloro-1,1,1-trifluoro-ethane. Proc. Natl. Acad. Sci. USA 1991, 88:1407-1410.
71. Mansuy D., Nastainczyk W., Ullrich V. The mechanism of halothane binding to microsomal cytochrome P450. Naunyn Schmiedebergs Arch. Pharmacol. 1974, 285:315-324.
72. Ahr H.J., King L.J., Nastainczyk W., Ullrich V. The mechanism of reductive dehalogenation of halothane by liver cytochrome P450. Biochem. Pharmacol. 1982, 31:383-390.
73. Pohl L.R. An immunochemical approach of identifying and characterizing protein targets of toxic reactive metabolites. Chem. Res. Toxicol. 1993, 6:786-793.
74. Kenna J.G., Neuberger J., Williams R. Evidence for expression in human liver of halothane-induced neoantigens recognized by antibodies in sera from patients with halothane hepatitis. Hepatology 1988, 8:1635-1641.
75. Pohl L.R., Kenna J.G., Satoh H., Christ D., Martin J.L. Neoantigens associated with halothane hepatitis. Drug Metab. Rev. 1989, 20:203-217.
76. Hoet P., Graf M.L., Bourdi M., Pohl L.R., Duray P.H., Chen W., Peter R.M., Nelson S.D., Verlinden N., Lison D. Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet 1997, 350:556-559.
77. Baillie T.A. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1988, 1:195-199.
78. Rettie A.E., Rettenmeier A.W., Howald W.N., Baillie T.A. Cytochrome P-450-catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 1987, 235:890-893.
79. Rettie A.E., Sheffels P.R., Korzekwa K.R., Gonzalez F.J., Philpot R.M., Baillie T.A. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid. Biochemistry 1995, 34:7889-7895.
80. Kassahun K., Baillie T.A. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically active metabolite of valproic acid in rat liver microsomal preparations. Drug Metab. Dispos. 1993, 21:242-248.
81. Prickett K.S., Baillie T.A. Metabolism of unsaturated derivatives of valproic acid in rat liver microsomes and destruction of cytochrome P-450. Drug Metab. Dispos. 1986, 14:221-229.
82. Ortiz de Montellano P.R., Yost G.S., Mico B.A., Dinizo S.E., Correia M.A., Kumbara H. Destruction of cytochrome P-450 by 2-isopropyl-4-pentenamide and methyl 2-isopropyl-4-pentenoate: mass spectrometric characterization of prosthetic heme adducts and nonparticipation of epoxide metabolites. Arch. Biochem. Biophys. 1979, 197:524-533.
83. Rettenmeier A.W., Gordon W.P., Prickett K.S., Levy R.H., Baillie T.A. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug Metab. Dispos. 1986, 14:454-464.
84. Rettenmeier A.W., Prickett K.S., Gordon W.P., Bjorge S.M., Chang S.L., Levy R.H., Baillie T.A. Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab. Dispos. 1985, 13:81-96.
85. Chang T.K., Abbott F.S. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab. Rev. 2006, 38:627-639.
86. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., Iwabuchi H., Nakamura T., Kinoshita T., Ikeda T., Yoshioka T., Komai T., Nakamura K. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats mice and dogs. Arzneimittelforschung 1997, 47:356-368.
87. Ramachandran V., Kostrubsky V.E., Komoroski B.J., Zhang S., Dorko K., Esplen J.E., Strom S.C., Venkataramanan R. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 1999, 27:1194-1199.
88. Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., Baillie T.A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 2001, 14:62-70.
89. Prabhu S., Fackett A., Lloyd S., McClellan H.A., Terrell C.M., Silber P.M., Li A.P. Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem. Biol. Interact. 2002, 142:83-97.
90. Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F.P., Yokoi T. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 1999, 27:1260-1266.
91. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 2003, 16:679-687.
92. Jaeschke H. Troglitazone hepatotoxicity: Are we getting closer to understanding idiosyncratic liver injury?. Toxicol. Sci. 2007, 97:1-3.
93. Ong M.M., Latchoumycandane C., Boelsterli U.A. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 2007, 97:205-213.
94. Zhou S., Chan E., Duan W., Huang M., Chen Y.Z. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. 2005, 37:41-213.
95. Yang X.X., Hu Z.P., Chan S.Y., Zhou S.F. Monitoring drug-protein interaction. Clin. Chim. Acta. 2006, 365:9-29.
96. Evans D.C., Watt A.P., Nicoll-Griffith D.A., Baillie T.A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004, 17:3-16.
97. Tang C., Subramanian R., Kuo Y., Krymgold S., Lu P., Kuduk S.D., Ng C., Feng D.M., Elmore C., Soli E., Ho J., Bock M.G., Baillie T.A., Prueksaritanont T. Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates. Chem. Res. Toxicol. 2005, 18:934-945.
98. Doss G.A., Baillie T.A. Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev. 2006, 38:641-649.
99. Baillie T.A., Cayen M.N., Fouda H., Gerson R.J., Green J.D., Grossman S.J., Klunk L.J., LeBlanc B., Perkins D.G., Shipley L.A. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 2002, 182:188-196.
100. Obach R.S., Walsky R.L., Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007, 35:246-255.
101. Kalgutkar A.S., Obach R.S., Maurer T.S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 2007, 8:407-447.
102. Guengerich F.P., MacDonald J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 2007, 20:344-369.